

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Pathophysiology*

**Manuscript NO:** 65503

**Title:** Current treatment strategies and future perspectives for gastrointestinal stromal tumors

**Reviewer's code:** 05574528

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** N/A, Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-08

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-22 09:48

**Reviewer performed review:** 2021-04-23 07:22

**Review time:** 21 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

This article pointed out three different GISTs corresponded to various management. Overall I found the article to read as a laundry list of abstracts of GISTs related studies rather than an in depth review of the findings and scientific value behind all of the studies. It is suggested that readers would appreciate a more synthesized overview of not only what research has been done, but which aligned (suggesting there may be something valuable to their findings) versus discordant and why they are discordant. Here are some other major issues: 1. The introduction is of redundancy and complications and needed to be simplify. The purpose of this review in introduction section should be consistent with the core tip section. 2. First part in the main text, “images” is recommended to be revised as “imaging”. The main idea of the whole article is not about submucosal tumor, and it is suggested to omit the irrelevant content about submucosal tumor. Rather, the focus is on depicting things of GISTs. 3. Third part of “UNRESECTABLE, RECURRENT OR METASTATIC GIST” is clunky and unclear, not as logic as the first part with subheadings. The table 4 at the end seems to do a better job than the text of the paper. Additionally, in terms of table 4, the advantage is the refinement treatment choices for specific exon mutations, but KIT gene also included exon 8,14,18, which lacks explanation in the article. And table 4 summaries are not complete and full, for example, wild type GISTs with BRAF mutation is sensitive to Dabrafenib based on pervious literature. 4. There are word choice and grammatical errors throughout the manuscript whose correction would improve readability. Additionally, the use of subheadings is not standardized and confusing. 5. Every table should be marked a detailed and separate abbreviation for comprehension. 6. The full text should be marked with a total abbreviation list.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Pathophysiology*

**Manuscript NO:** 65503

**Title:** Current treatment strategies and future perspectives for gastrointestinal stromal tumors

**Reviewer's code:** 03769712

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-08

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-26 03:34

**Reviewer performed review:** 2021-04-27 13:28

**Review time:** 1 Day and 9 Hours

<b>Scientific quality</b>	[ <input checked="" type="radio"/> ] Grade A: Excellent [ <input type="radio"/> ] Grade B: Very good [ <input type="radio"/> ] Grade C: Good [ <input type="radio"/> ] Grade D: Fair [ <input type="radio"/> ] Grade E: Do not publish
<b>Language quality</b>	[ <input checked="" type="radio"/> ] Grade A: Priority publishing [ <input type="radio"/> ] Grade B: Minor language polishing [ <input type="radio"/> ] Grade C: A great deal of language polishing [ <input type="radio"/> ] Grade D: Rejection
<b>Conclusion</b>	[ <input checked="" type="radio"/> ] Accept (High priority) [ <input type="radio"/> ] Accept (General priority) [ <input type="radio"/> ] Minor revision [ <input type="radio"/> ] Major revision [ <input type="radio"/> ] Rejection
<b>Re-review</b>	[ <input checked="" type="radio"/> ] Yes [ <input type="radio"/> ] No
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

#### **SPECIFIC COMMENTS TO AUTHORS**

1.The manuscript discussed treatment strategies for current GIST and promising treatments based on clinical trial. In addition, the application of more surgical techniques in the field of GIST is described. 2.The language quality in the manuscript is good. 3.The evidence on diagnosis, treatment, and prognosis is overwhelming.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Pathophysiology*

**Manuscript NO:** 65503

**Title:** Current treatment strategies and future perspectives for gastrointestinal stromal tumors

**Reviewer's code:** 02441006

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Chief Doctor, Doctor, Senior Researcher

**Reviewer's Country/Territory:** Czech Republic

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2021-03-08

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-25 15:01

**Reviewer performed review:** 2021-05-10 02:15

**Review time:** 14 Days and 11 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

Although the manuscript contains much important information on the issue of gastrointestinal stromal tumor treatment, in my opinion, unfortunately, it does not meet for comprehensive review. The text is too general, it includes issues of surgery, neoadjuvant treatment, adjuvant treatment and palliative therapy. This is the reason why it does not go into too much detail of the discussed topics. The text seems to me more like a chapter in a textbook. Therefore I have to recommend to the authors to divide the text into two or more parts (e.g. surgery and systemic therapy) and elaborate the information into greater details. I have less important comment on the term "neoadjuvant chemotherapy" which is used in the text and even in the abstract. Imatinib is a targeted therapy, therefore I do not recommend to use a term chemotherapy for imatinib. GIST is considered to be chemoresistant and chemotherapy is usually used for the treatment of GIST. My recommendations for the editorial board is to accept the article for publication but after for major editing of the text.